PLIVA Announces FDA Approval of SANCTURA
PLIVA d.d. (“PLIVA”) announced today that the US Food and Drug Administration (FDA) has approved SANCTURA™ (trospium chloride tablets), which is indicated for the treatment of overactive bladder (OAB), with symptoms of urge urinary incontinence, urgency and urinary frequency.
Zagreb, 31 May 2004
- PR FDA Approval SANCTURA 31May2004.pdf ( 85,4 KB)